Literature DB >> 25557742

Purified type I collagen wound matrix improves chronic wound healing in patients with recessive dystrophic epidermolysis bullosa.

Emily S Gorell1, Thomas H Leung, Phuong Khuu, Alfred T Lane.   

Abstract

Recessive dystrophic epidermolysis bullosa is a severe genetic blistering skin condition resulting in chronic wounds. Nonhealing wounds were treated over 8 weeks using a reconstituted natural purified type I collagen skin substitute. Chronic wounds were defined as nonhealing wounds present for longer than 6 months. For each patient, two chronic wounds were identified and randomized into a control or treatment group. Both groups received standard-of-care wound dressings. The treatment group received an additional type I collagen skin substitute. Wound size was measured at baseline and weeks 1, 4, and 8. Pain, pruritus, and burning and stinging were assessed. Wound cultures were obtained at baseline and thereafter as was considered clinically relevant. Ten subjects were enrolled; seven completed the study. Six subjects showed a positive response to the type I collagen skin substitute. Three subjects demonstrated full wound reepithelialization. Wounds treated using the collagen skin substitute showed statistically significantly greater improvement. Average scores for pruritus and pain decreased significantly. Reconstituted natural purified type I collagen skin substitutes improved the healing of chronic wounds and may be a valuable addition to the epidermolysis bullosa wound care arsenal.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25557742     DOI: 10.1111/pde.12492

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  6 in total

1.  Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America.

Authors:  James A Feinstein; Purevsuren Jambal; Kathleen Peoples; Anne W Lucky; Phuong Khuu; Jean Y Tang; Irene Lara-Corrales; Elena Pope; Karen Wiss; Kristen P Hook; Laura E Levin; Kimberly D Morel; Amy S Paller; Catherine C McCuaig; Julie Powell; Lawrence F Eichenfield; Harper Price; Moise L Levy; Lawrence A Schachner; John C Browning; Susan Bayliss; Marla Jahnke; Tor Shwayder; Sharon A Glick; Anna L Bruckner
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

Review 2.  Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa.

Authors:  Ellie Rashidghamat; John A McGrath
Journal:  Intractable Rare Dis Res       Date:  2017-02

3.  Ex Vivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Using CRISPR/Cas9 and Homology-Directed Repair.

Authors:  Araksya Izmiryan; Clarisse Ganier; Matteo Bovolenta; Alain Schmitt; Fulvio Mavilio; Alain Hovnanian
Journal:  Mol Ther Nucleic Acids       Date:  2018-06-26       Impact factor: 8.886

4.  Evaluation of Bovine-Derived Collagen Membrane in Oral Surgical Mucosal Defects.

Authors:  Devakumari Shanmugam; Neil Dominic
Journal:  J Maxillofac Oral Surg       Date:  2018-11-17

5.  Shotgun label-free proteomic analysis for identification of proteins in HaCaT human skin keratinocytes regulated by the administration of collagen from soft-shelled turtle.

Authors:  Tetsushi Yamamoto; Saori Nakanishi; Kuniko Mitamura; Atsushi Taga
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2017-11-28       Impact factor: 3.368

6.  Integra®-Dermal Regeneration Template and Split-Thickness Skin Grafting: A Therapy Approach to Correct Aplasia Cutis Congenita and Epidermolysis Bullosa in Carmi Syndrome.

Authors:  Julian Trah; Christina Has; Ingrid Hausser; Heinz Kutzner; Konrad Reinshagen; Ingo Königs
Journal:  Dermatol Ther (Heidelb)       Date:  2018-05-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.